The effects of dietary selenomethionine on polyamines and azoxymethane-induced aberrant crypts.
We evaluated the effects of dietary selenomethionine supplementation on colonic polyamine levels and the ability of L-selenomethionine supplementation to modulate the carcinogenic activity of azoxymethane (AOM) in the rat colon. Four-week-old male F344 rats were treated with 15 mg/kg body weight of AOM once a week for 2 weeks. Dietary selenomethionine at a concentration of either 1 or 2 ppm was administered in AIN-76A rodent diet to AOM-treated animals for 16 weeks. Aberrant crypt foci (ACF), precursor lesions of colon cancer, were investigated after the 16 week treatment course. Selenomethionine given in the diet at 2 ppm markedly reduced the number of aberrant crypt foci. The multiplicity of ACFs (i.e. the number of aberrant crypts/focus) and the percentage of microadenomas were also affected by selenomethionine in a dose dependent manner. However, evaluation of the colonic tissue polyamine levels between control and treated groups showed no significant difference. These results demonstrate that selenomethionine can modulate the development of AOM-induced premalignant lesions through a polyamine-independent mechanism.
Baines
A T
AT
Pharmacology/Toxicology Department, The University of Arizona, Tucson, AZ, USA.
Holubec
H
H
Basye
J L
JL
Thorne
P
P
Bhattacharyya
A K
AK
Spallholz
J
J
Shriver
B
B
Cui
H
H
Roe
D
D
Clark
L C
LC
Earnest
D L
DL
Nelson
M A
MA
D000410:Alanine Transaminase; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D001397:Azoxymethane; D015317:Biogenic Polyamines / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens; D003106:Colon / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D011230:Precancerous Conditions / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D051381:Rats; D011916:Rats, Inbred F344; D012643:Selenium / Q000097:blood; D012645:Selenomethionine / Q000494:pharmacology*
D016588:Anticarcinogenic Agents; D015317:Biogenic Polyamines; D002273:Carcinogens; D012645:Selenomethionine; D000410:Alanine Transaminase; D012643:Selenium; D001397:Azoxymethane